Comprehensive Immunotherapy Efficacy Evaluation

Evaluating immunotherapy efficacy requires a model that retains functional immune cells over the duration of a study. Standard models lose immune cells within days, making it impossible to assess T-cell exhaustion, cytokine dynamics, or long-term immune response.

Part I — ICB Evaluation: ccRCC and NSCLC PDO models were established with IL-2 supplementation. T-cell retention was monitored over 28 days. ICB treatment was applied and anti-tumor immune response was quantified.

Part II — Bi-specific Antibody: The same platform was applied to evaluate a BsAb targeting both tumor and immune cells.

Part I: TIL retention >4 weeks. ICB-induced measurable CD8+ T and NK cell activation with tumor killing quantified by FACS.

Part II: BsAb-induced CD8+ T and NK cell activation with tumor killing quantification by flow cytometry, qPCR, and ELISA.

Provides a comprehensive, multi-readout platform for evaluating checkpoint inhibitors and next-generation immunotherapies including bi-specific antibodies and cell therapies.